Cas:6639-91-4 1,2,3,4-Tetrahydro-quinoxalin-6-ylamine manufacturer & supplier

We serve Chemical Name:1,2,3,4-Tetrahydro-quinoxalin-6-ylamine CAS:6639-91-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,2,3,4-Tetrahydro-quinoxalin-6-ylamine

Chemical Name:1,2,3,4-Tetrahydro-quinoxalin-6-ylamine
CAS.NO:6639-91-4
Synonyms:1,2,3,4-Tetrahydro-quinoxalin-6-ylamine
Molecular Formula:C8H11N3
Molecular Weight:149.19300
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:359.9ºC at 760 mmHg
Density:1.142g/cm3
Index of Refraction:1.601
PSA:50.08000
Exact Mass:149.09500
LogP:1.96340

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,2,3,4-Tetrahydro-quinoxalin-6-ylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3,4-Tetrahydro-quinoxalin-6-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3,4-Tetrahydro-quinoxalin-6-ylamine Use and application,1,2,3,4-Tetrahydro-quinoxalin-6-ylamine technical grade,usp/ep/jp grade.


Related News: Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. N-(2-Aminoethyl)-3′-({[(2E)-3-(4-fluorophenyl)-2-propenoyl](1-naphthylmethyl)amino}methyl)-1,1′-biphenyl-2-carboxamide trifluoroacetate manufacturers CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up. (1H-imidazol-4-yl)-acetic acid ethyl ester suppliers McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. Imidodicarbonic acid, methyl-, 4-bromophenyl methyl ester vendor & factory.